Table1 Characteristics of patients with severe therapy-resistant asthma (STRA) n = 13

Clinical and demographic data at visit 1

Age in years, mean (SD)

12.45 (2.73)

Male sex (%)

69.3%

Age at onset of symptoms in months, mean (SD)

12.5 (2.7)

Mean BMI* Z score (SD)

0.9369 (1.092)

Mean height Z score (DP)

-0.200 (0.9615)

Exposure to smokers (%)

23%

Almost fatal crisis (%)

38.4%

Obesity (%)

11.2%

Sinusopathy (%)

42.3%

Treatment

Budesonide 800 mcg/day (%)

92.3%

Fluticasone 500 mcg/day (%)

7.7%

Oral steroid (Visit 1) (%)

7.8%

LABA (%)

100%

LTRA (%)

69.2%

Nasal steroid (%)

100%

Good adherence (≥ 85%) to treatment- visit 1 (%)

69.2%

Good adherence (≥ 85%) to treatment -visit 3 (%)

84.6%

Follow-up data (visit 3)

ACT ** – mean (SD) visit 1

15,3 (3,43)

ACT ** – mean (SD) visit 3

15,5 (3,77)

Atopy *** (%)

92%

Serum IgE IU/ml median (min–max)

811.0 (4.0–4.740.0)

Pulmonary function tests – mean (SD) (visit 3)

Pre-BD FEV1

82.87% (24.35)

Pre-BD FVC

99.74 (19.48)

Pre-BD FEF 25–75%

57.73% (30.03)

Pre-BD FEV1/SVC

72.15% (13.26)

Pre-BD TLC

98.50% (13.24)

Pre-BD RV

130.4% (56.79)

Pre-BD RV/TLC

23.92% (11.66)

Pre-BD Resistance

150.5% (74.34)

Pre-BD Conductance

44.75% (20.26)

Post-BD variation in FEV1 – median (IQR)

14% (6,75%–19%)

Post-BD variation in conductance – median (IQR)

60,2% (36,2%-93,9%)

Noninvasive assessment of inflammation

Blood eosinophils/mm³ median (min–max)

533.9 (96.2–2.202.9)

FeNO (ppb) median (min–max)

31.0 (7.0–103.0)

Sputum total cells × 10⁶ (visit 1) median (min–max)

1.86 (0.3–5.0)

Sputum total cells × 10⁶ (visit 3) median (min–max)

3.60 (1.2–6.6)

% Sputum Eosinophils (visit 1) median (min–max)

14,1% (0,4–65,2)

% Sputum Eosinophils (visit 3) median (min–max)

3,48% (0–66,67)

% Sputum neutrophils (visit 1) median (min–max)

43,6% (4,2–87,6)

% Sputum neutrophils (visit 3) median (min–max)

44,68% (7,6–74,5)